The literature has revealed no reports of antiviral activity associated with phosphonoacetic acid (PAA) or its analogues. PAA has been known since 1924 (24) . Compounds containing a carbon to phosphorous bond are rare in nature, and until recently were thought to be nonexistent (7). Inglot et al. (17) (18) (19) (20) reported the antiviral activity of benzyl phosphonic acid against encephalomyocarditis virus which is a picornavirus and completely unrelated to herpesvirus.
Random testing of compounds with a tissue culture screen designed to detect antiviral compounds revealed that PAA inhibited replication of herpesvirus types 1 The topical application of disodium phosphonoacetic acid to the eyes of rabbits for 3 days after they were experimentally infected with herpesvirus produced the following results ( Table 2) .
A 5% drug-in-liquid treatment or 5, 2, 1, or 0.5% drug-in-ointment treatment reduced corneal lesions from 5 to 9 days after infection. After 10 days, the lesion scores between treated and untreated groups were not significantly different. Drug concentrations below 0.5% were not effective with the exception of one group in the 0.05% series.
Herpes keratitis is a self-limiting infection of b Duncan multiple range test (9) . Abbreviations (at P0.05 level): S, significant; N, not significant. the eye. As time progresses after the infection, the eye lesions become less severe and eventually disappear. However, during the early, acute phase of the infection disodium phosphonoacetic acid in concentrations greater than 0.5% was able to reduce the lesions caused by the virus. In the experimental design of this experiment, both eyes of a rabbit were infected; the right was treated while the left acted as the infected control. Probably as a result of this design, herpesvirus was in some instances able to cause central nervous system involvement and death of the rabbits. DISCUSSION After a tissue culture screen revealed that PAA inhibited replication of herpesvirus types 1 and 2, several analogues were also tested in tissue culture. The structural requirements for activity were very rigorous. The triethyl ester (3) was tested and found to be devoid of activity, as were phosphonopropionic acid, disodium phosphonobutyrate, and disodium amethyl phosphonoacetate. To be certain that the activity of the free acid was not attributable to a pH effect, acetic and phosphoric acids were also tested at equivalent molar concentrations in tissue culture. Both were inactive.
Disodium phosphonoacetic acid was chosen to test in vivo efficacy. The animal models used were herpes dermatitis in mice, utilizing type 2 virus, and herpes keratitis in rabbits, utilizing type 1 virus. The compound was found to be effective against the dermatitis when applied topically in concentrations of from 0.5 to 5.0% and when administered orally at a dosage range of from 800 to 1,400 jig per kg per day for 6 days.
The corneal lesions caused by herpesvirus, type 2, were significantly reduced in severity when the compound was applied topically at concentrations of 0.5 to 5.0%.
It should be noted that in our in vivo studies, drug treatment began 2 h after virus inoculation. This model system does not allow a direct comparison with human infections where virus has been present for weeks or years in latent form. Nevertheless, in an initial animal test system every attempt should be made to permit the drug to reveal its potential. Further experiments are planned to demonstrate the effects of the drug in chronic infections in animals.
It is quite surprising that a compound as highly charged as PAA can penetrate the cell membrane. Perhaps the active moiety is not PAA but a derivative of PAA. However, determination of this requires further work.
Herpes dermatitis in man is a very common though usually minor disease for which no effective form of therapy exists (29) . Better control of this condition could result in fewer cases of herpes keratitis, the single most common corneal infection in the United States (2). The great reduction in the mortality of mice infected with herpesvirus and treated with disodium phosphonoacetate suggests that this compound might be effectively used in herpes encephalitis. The nature of this condition is so serious that even a drug of low therapeutic ratio would be useful (6) . A common complication of presently available immunosuppressive therapy is increased susceptibility to herpesvirus infection. Normally a benign though annoying resident of the body, the virus may become activated and produce a fatal infection in the presence of lowered host resistance (8) . This compound could be useful in such situations.
Serologic and epidemiologic studies have suggested an implication of herpesviruses with certain types of cancer in animals (12, 14-16, 21, 25) including humans (1, 4-5, 10, 13, 22-23, 26-27 
